Dr Thierry Andre speaks to ecancer about the first results of nivolumab plus ipilimumab versus nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HWA.

This is a phase three study that investigates treatment options for metastatic colorectal cancer patients with MSI or DMMR.

It compares nivolumab plus ipilimumab against nivolumab alone, focusing on progression-free survival (PFS).

Results show that combination therapy significantly improves PFS, with 71% of patients on the combination remaining progression-free at two years, compared to 56% on nivolumab alone.

These findings suggest a potential new standard of care.